top of page
  • Recruiting

NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

Updated: Sep 29, 2022

GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125

NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

MCARH125-MCARH109

NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma


A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.


Sponsor

Memorial Sloan Kettering Cancer Center

 

ClinicalTrials.gov Identifier: NCT05431608

Official Title: Phase I Trial of Concurrent Administration of GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125 in Patients With Relapsed or Refractory Multiple Myeloma

First Posted : June 24, 2022

Click here for details on ClinicalTrials.gov

 

GPRC5D-Targeted CAR T Cell MCARH109

MCARH109

Autologous Anti-GPRC5D-CAR-4-1BB-expressing T-cells MCARH109 (Code C176222)

Autologous Anti-GPRC5D CAR-T Cells MCARH109

Autologous Anti-GPRC5D-CAR-4-1BB-expressing T-cells MCARH109

Autologous GPRC5D-targeted CAR T Cells MCARH109

MCARH 109

MCARH-109

MCARH109